Prevalence and clinical outcomes of the 46/1 haplotype, Janus kinase 2 mutations, and ten-eleven translocation 2 mutations in budd-chiari syndrome and their impact on thrombotic complications post Liver Transplantation

Liver Transplantation

Volumn 18, Issue 7, 2012, Pages 819-827

  Westbrook, Rachel H ^a   Lea, Nicholas C ^a   Mohamedali, Azim M ^a   Smith, Alexander E ^a   Orr, David W ^a   Roberts, Lara N ^a   Heaton, Nigel D ^a   Wendon, Julia A ^a   O'Grady, John G ^a   Heneghan, Michael A ^a   Mufti, Ghulam J ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

ADOLESCENT; ADULT; AGED; ARTICLE; BUDD CHIARI SYNDROME; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE; GENE FREQUENCY; GENE MUTATION; HAPLOTYPE; HUMAN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PREVALENCE; PRIORITY JOURNAL; RETRANSPLANTATION; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL; TET2 GENE; THROMBOSIS;

ADOLESCENT; ADULT; AGED; BUDD-CHIARI SYNDROME; CHROMOSOME ABERRATIONS; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; HAPLOTYPES; HUMANS; JANUS KINASE 2; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MUTATION; PREVALENCE; PROSPECTIVE STUDIES; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 84863972671     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23443     Document Type: Article

References (41)

1. Ludwig J, Hashimoto E, McGill DB, van Heerden JA,. Classification of hepatic venous outflow obstruction: ambiguous terminology of the Budd-Chiari syndrome. Mayo Clin Proc 1990; 65: 51-55.
2. Menon KV, Shah V, Kamath PS,. The Budd-Chiari syndrome. N Engl J Med 2004; 350: 578-585.
3. Pagliuca A, Mufti GJ, Janossa-Tahernia M, Eridani S, Westwood NB, Thumpston J, et al. In vitro colony culture and chromosomal studies in hepatic and portal vein thrombosis-possible evidence of an occult myeloproliferative state. Q J Med 1990; 76: 981-989.
4. Valla D, Casadevall N, Lacombe C, Varet B, Goldwasser E, Franco D, et al. Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Ann Intern Med 1985; 103: 329-334.
5. Valla D, Casadevall N, Huisse MG, Tulliez M, Grange JD, Muller O, et al. Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. Gastroenterology 1988; 94: 1063-1069.
6. De Stefano V, Teofili L, Leone G, Michiels JJ,. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost 1997; 23: 411-418.
7. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature 2005; 434: 1144-1148.
8. James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
9. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
10. Patel RK, Lea NC, Heneghan MA, Westwood NB, Milojkovic D, Thanigaikumar M, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 2006; 130: 2031-2038.
11. DeLeve LD, Valla DC, Garcia-Tsao G,; for American Association for the Study of Liver Diseases. Vascular disorders of the liver. Hepatology 2009; 49: 1729-1764.
12. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162-2168.
13. Lasho TL, Pardanani A, McClure RF, Mesa RA, Levine RL, Gilliland DG, Tefferi A,. Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. Br J Haematol 2006; 135: 683-687.
14. Kralovics R,. Genetic complexity of myeloproliferative neoplasms. Leukemia 2008; 22: 1841-1848.
15. Bellanné-Chantelot C, Chaumarel I, Labopin M, Bellanger F, Barbu V, De Toma C, et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 2006; 108: 346-352.
16. Landgren O, Goldin LR, Kristinsson SY, Helgadottir EA, Samuelsson J, Björkholm M,. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. Blood 2008; 112: 2199-2204.
17. Rumi E, Passamonti F, Picone C, Della Porta MG, Pascutto C, Cazzola M, Lazzarino M,. Disease anticipation in familial myeloproliferative neoplasms. Blood 2008; 112: 2587-2588.
18. Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009; 41: 446-449.
19. Olcaydu D, Harutyunyan A, Jäger R, Berg T, Gisslinger B, Pabinger I, et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 2009; 41: 450-454.
20. Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL, et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 2009; 41: 455-459.
21. Tefferi A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Patnaik MM, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009; 23: 1343-1345.
22. Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009; 23: 905-911.
23. Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009; 41: 838-842.
24. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360: 2289-2301.
25. Plessier A, Sibert A, Consigny Y, Hakime A, Zappa M, Denninger MH, et al. Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome. Hepatology 2006; 44: 1308-1316.
26. Tavill AS, Wood EJ, Kreel L, Jones EA, Gregory M, Sherlock S,. The Budd-Chiari syndrome: correlation between hepatic scintigraphy and the clinical, radiological, and pathological findings in nineteen cases of hepatic venous outflow obstruction. Gastroenterology 1975; 68: 509-518.
27. Halff G, Todo S, Tzakis AG, Gordon RD, Starzl TE,. Liver transplantation for the Budd-Chiari syndrome. Ann Surg 1990; 211: 43-49.
28. Ringe B, Lang H, Oldhafer KJ, Gebel M, Flemming P, Georgii A, et al. Which is the best surgery for Budd-Chiari syndrome: venous decompression or liver transplantation? A single-center experience with 50 patients. Hepatology 1995; 21: 1337-1344.
29. Eapen CE, Velissaris D, Heydtmann M, Gunson B, Olliff S, Elias E,. Favourable medium term outcome following hepatic vein recanalisation and/or transjugular intrahepatic portosystemic shunt for Budd Chiari syndrome. Gut 2006; 55: 878-884.
30. Mackiewicz A, Kotulski M, Zieniewicz K, Krawczyk M., Results of liver transplantation in the treatment of Budd-Chiari syndrome. Ann Transplant 2012; 17: 5-10.
31. Chinnakotla S, Klintmalm GB, Kim P, Tomiyama K, Klintmalm E, Davis GL, Trotter JF, Saad R, Landaverde C, Levy MF, Goldstein RM, Stone MJ,. Long-term follow-up of liver transplantation for Budd-Chiari syndrome with antithrombotic therapy based on the etiology. Transplantation 2011; 92: 341-345.
32. Mentha G, Giostra E, Majno PE, Bechstein WO, Neuhaus P, O'Grady J, et al. Liver transplantation for Budd-Chiari syndrome: a European study on 248 patients from 51 centres. J Hepatol 2006; 44: 520-528.
33. Daly S, Conneally E, Langabeer SE,. Identification of MPL W515L/K mutations in patients with primary myelofibrosis and essential thrombocythaemia by allele-specific polymerase chain reaction. Acta Haematol 2009; 121: 221-222.
34. Mohamedali A, Gäken J, Twine NA, Ingram W, Westwood N, Lea NC, et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 2007; 110: 3365-3373.
35. Smith AE, Mohamedali AM, Kulasekararaj A, Lim Z, Gäken J, Lea NC, et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 2010; 116: 3923-3932.
36. Mohamedali AM, Smith AE, Gaken J, Lea NC, Mian SA, Westwood NB, et al. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. J Clin Oncol 2009; 27: 4002-4006.
37. Melear JM, Goldstein RM, Levy MF, Molmenti EP, Cooper B, Netto GJ, et al. Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders. Transplantation 2002; 74: 1090-1095.
38. Chinnakotla S, Klintmalm GB, Kim P, Tomiyama K, Klintmalm E, Davis GL, et al. Long-term follow-up of liver transplantation for Budd-Chiari syndrome with antithrombotic therapy based on the etiology. Transplantation 2011; 92: 341-345.
39. Smalberg JH, Koehler E, Darwish Murad S, Plessier A, Seijo S, Trebicka J, et al.; for European Network for Vascular Disorders of the Liver. The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis. Blood 2011; 117: 3968-3973.
40. Valla DC,. Thrombosis and anticoagulation in liver disease. Hepatology 2008; 47: 1384-1393.
41. Darwish Murad S, Plessier A, Hernandez-Guerra M, Fabris F, Eapen CE, Bahr MJ, et al.; for European Network for Vascular Disorders of the Liver. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med 2009; 151: 167-175.